Speakers:  Mathias Uhlén, Professor at Science for Life Laboratory and Albanova University Center, Royal Institute of Technology (KTH) & Ida Grundberg, Chief Scientific Officer at Olink Proteomics

Original Broadcast date:  September 02 2020

New high-throughput 'omics tools capable of performing genomic, proteomic, and metabolomic analysis using clinical samples have opened up unique possibilities to study both health and disease with high analytical precision and clinical accuracy. Studying the proteins secreted into the bloodstream can provide insights into many important biological processes as well as potential targets for diagnostics and therapies. Multiplex technologies enabling the analysis of thousands of protein targets from minute amounts of plasma or serum have opened up a new field in precision medicine, in which the levels of thousands of blood proteins can be efficiently monitored. This allows for variations in protein concentrations within an individual to be tracked over time—including during drug treatment—and for comparisons to be drawn between healthy and diseased individuals. In this webinar, our expert speakers will describe two multiplex platforms used to rapidly analyze blood proteins using quantitative PCR and next-generation sequencing, which have been instrumental in a 2-year longitudinal wellness study involving repeated sampling of individuals. Analysis included classical clinical chemistry, advanced medical imaging, and extensive 'omics profiling focusing on the plasma proteome and completed by whole-genome sequencing, as well as an exploration of the plasma metabolome, the transcriptome, blood-cell composition (immune cytome), autoantibody reactivity profiles, and gut microbiota composition.

This webinar covers the following points:

• Assays that can be used to analyze more than a thousand protein targets in blood from very small blood samples
• A longitudinal wellness study showing that individuals have unique, stable plasma protein profiles that correlate strongly with clinical chemistry parameters
• Blood proteins that are impacted by drug treatment, as exemplified by the analysis of patients treated for type 2 diabetes
• Results that support an individual-based definition of health and show the advantages of longitudinal 'omics profiling for precision medicine.

If you have any questions about Olink, please contact us at info@olink.com.